Compare JUBILANT LIFE SCIENCES with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs DISHMAN PHARMA - Comparison Results

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES DISHMAN PHARMA JUBILANT LIFE SCIENCES/
DISHMAN PHARMA
 
P/E (TTM) x 13.0 25.1 52.0% View Chart
P/BV x 1.6 3.3 48.7% View Chart
Dividend Yield % 0.9 0.7 137.6%  

Financials

 JUBILANT LIFE SCIENCES   DISHMAN PHARMA
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-19
DISHMAN PHARMA
Mar-16
JUBILANT LIFE SCIENCES/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs898374 239.9%   
Low Rs618129 479.1%   
Sales per share (Unadj.) Rs572.0197.8 289.2%  
Earnings per share (Unadj.) Rs36.221.2 170.8%  
Cash flow per share (Unadj.) Rs59.534.7 171.4%  
Dividends per share (Unadj.) Rs4.502.00 225.0%  
Dividend yield (eoy) %0.60.8 74.7%  
Book value per share (Unadj.) Rs301.9179.9 167.8%  
Shares outstanding (eoy) m159.2880.69 197.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.31.3 104.1%   
Avg P/E ratio x20.911.9 176.3%  
P/CF ratio (eoy) x12.77.2 175.7%  
Price / Book Value ratio x2.51.4 179.4%  
Dividend payout %12.49.4 131.7%   
Avg Mkt Cap Rs m120,69420,306 594.4%   
No. of employees `0002.40.8 288.3%   
Total wages/salary Rs m19,2605,355 359.7%   
Avg. sales/employee Rs Th38,120.619,252.7 198.0%   
Avg. wages/employee Rs Th8,058.46,459.5 124.8%   
Avg. net profit/employee Rs Th2,414.32,064.1 117.0%   
INCOME DATA
Net Sales Rs m91,10815,961 570.8%  
Other income Rs m357265 134.7%   
Total revenues Rs m91,46616,226 563.7%   
Gross profit Rs m17,3904,103 423.8%  
Depreciation Rs m3,7091,091 340.1%   
Interest Rs m2,198944 232.8%   
Profit before tax Rs m11,8402,334 507.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m-2,8020-   
Tax Rs m3,268624 524.1%   
Profit after tax Rs m5,7701,711 337.2%  
Gross profit margin %19.125.7 74.2%  
Effective tax rate %27.626.7 103.3%   
Net profit margin %6.310.7 59.1%  
BALANCE SHEET DATA
Current assets Rs m45,84811,018 416.1%   
Current liabilities Rs m20,8979,517 219.6%   
Net working cap to sales %27.49.4 291.2%  
Current ratio x2.21.2 189.5%  
Inventory Days Days57110 51.4%  
Debtors Days Days5135 146.2%  
Net fixed assets Rs m65,49816,304 401.7%   
Share capital Rs m159161 98.7%   
"Free" reserves Rs m47,93012,907 371.4%   
Net worth Rs m48,08914,516 331.3%   
Long term debt Rs m42,4294,189 1,012.8%   
Total assets Rs m114,68529,805 384.8%  
Interest coverage x6.43.5 184.0%   
Debt to equity ratio x0.90.3 305.7%  
Sales to assets ratio x0.80.5 148.4%   
Return on assets %6.98.9 78.0%  
Return on equity %12.011.8 101.8%  
Return on capital %12.417.5 70.8%  
Exports to sales %024.8 0.0%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m12,4224,952 250.9%   
Fx outflow Rs m17,227697 2,472.3%   
Net fx Rs m-4,8054,255 -112.9%   
CASH FLOW
From Operations Rs m11,2152,786 402.5%  
From Investments Rs m-10,118-1,529 661.8%  
From Financial Activity Rs m6,574-941 -698.6%  
Net Cashflow Rs m7,612316 2,405.9%  

Share Holding

Indian Promoters % 45.6 61.4 74.3%  
Foreign collaborators % 3.5 0.0 -  
Indian inst/Mut Fund % 8.7 3.7 235.1%  
FIIs % 21.2 12.7 166.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 22.1 95.5%  
Shareholders   23,815 46,261 51.5%  
Pledged promoter(s) holding % 15.9 35.8 44.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   PIRAMAL ENTERPRISES  NOVARTIS  PANACEA BIOTECH  DR. REDDYS LAB  GSK PHARMA  

Compare JUBILANT LIFE SCIENCES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 70 Points Higher; Telecom and Banking Stocks Advance(Closing)

Indian share markets traded on a positive note throughout the day and ended marginally higher. The BSE Sensex rose over 350 points intraday.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY20); Net Profit Up 18.9% (Quarterly Result Update)

Oct 31, 2019 | Updated on Oct 31, 2019

For the quarter ended September 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 18.9% YoY). Sales on the other hand came in at Rs 23 bn (down 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Nov 15, 2019 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES - FRESENIUS KABI ONCO. COMPARISON

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS